XML 19 R9.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Revenue (Notes) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2024 | Jul. 02, 2023 | Jun. 30, 2024 | Jul. 02, 2023
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer [Text Block] |  |  | Revenue Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical markets and major goods and service lines.
| Reportable Segments
| Three Months Ended
| June 30, 2024 |  | July 2, 2023
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Primary geographical markets |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 168,413 |  |  | $ | 139,370 |  |  | $ | 307,783 |  |  | $ | 184,795 |  |  | $ | 134,032 |  |  | $ | 318,827 |
Europe | 67,358 |  |  | 117,230 |  |  | 184,588 |  |  | 74,707 |  |  | 116,910 |  |  | 191,617 |
Asia | 78,076 |  |  | 121,238 |  |  | 199,314 |  |  | 76,851 |  |  | 121,771 |  |  | 198,622 |
| $ | 313,847 |  |  | $ | 377,838 |  |  | $ | 691,685 |  |  | $ | 336,353 |  |  | $ | 372,713 |  |  | $ | 709,066 |
Major goods/service lines |  |  |  |  |  |  |  |  |  |  |
Life Sciences reagents | $ | 176,852 |  |  | $ | — |  |  | $ | 176,852 |  |  | $ | 192,208 |  |  | $ | — |  |  | $ | 192,208 |
Life Sciences instruments | 86,252 |  |  | — |  |  | 86,252 |  |  | 100,101 |  |  | — |  |  | 100,101 |
Life Sciences software | 50,743 |  |  | — |  |  | 50,743 |  |  | 44,044 |  |  | — |  |  | 44,044 |
Reproductive health | — |  |  | 129,175 |  |  | 129,175 |  |  | — |  |  | 128,621 |  |  | 128,621 |
Applied genomics | — |  |  | 51,287 |  |  | 51,287 |  |  | — |  |  | 59,097 |  |  | 59,097 |
Immunodiagnostics | — |  |  | 197,376 |  |  | 197,376 |  |  | — |  |  | 184,995 |  |  | 184,995 |
| $ | 313,847 |  |  | $ | 377,838 |  |  | $ | 691,685 |  |  | $ | 336,353 |  |  | $ | 372,713 |  |  | $ | 709,066 |
| Reportable Segments
| Six Months Ended
| June 30, 2024 |  | July 2, 2023
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Primary geographical markets |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 324,741 |  |  | $ | 277,396 |  |  | $ | 602,137 |  |  | $ | 348,649 |  |  | $ | 272,206 |  |  | $ | 620,855 |
Europe | 137,003 |  |  | 226,147 |  |  | 363,150 |  |  | 154,992 |  |  | 221,522 |  |  | 376,514 |
Asia | 155,140 |  |  | 221,178 |  |  | 376,318 |  |  | 161,153 |  |  | 225,409 |  |  | 386,562 |
| $ | 616,884 |  |  | $ | 724,721 |  |  | $ | 1,341,605 |  |  | $ | 664,794 |  |  | $ | 719,137 |  |  | $ | 1,383,931 |
Major goods/service lines |  |  |  |  |  |  |  |  |  |  |
Life Sciences reagents | $ | 354,077 |  |  | $ | — |  |  | $ | 354,077 |  |  | $ | 382,086 |  |  | $ | — |  |  | $ | 382,086 |
Life Sciences instruments | 167,162 |  |  | — |  |  | 167,162 |  |  | 196,275 |  |  | — |  |  | 196,275 |
Life Sciences software | 95,645 |  |  | — |  |  | 95,645 |  |  | 86,433 |  |  | — |  |  | 86,433 |
Reproductive health | — |  |  | 253,050 |  |  | 253,050 |  |  | — |  |  | 250,742 |  |  | 250,742 |
Applied genomics | — |  |  | 98,734 |  |  | 98,734 |  |  | — |  |  | 122,507 |  |  | 122,507 |
Immunodiagnostics | — |  |  | 372,937 |  |  | 372,937 |  |  | — |  |  | 345,888 |  |  | 345,888 |
| $ | 616,884 |  |  | $ | 724,721 |  |  | $ | 1,341,605 |  |  | $ | 664,794 |  |  | $ | 719,137 |  |  | $ | 1,383,931 |
Contract Balances Contract assets: The unbilled receivables (contract assets) primarily relate to the Company’s right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in “Accounts receivable, net” in the condensed consolidated balance sheets. Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related services for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in “Accounts payable” or “Accrued expenses and other current liabilities” or as long-term in “Long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The contract liability balances at the beginning of each period presented were generally fully recognized in the subsequent three month period. The performance obligations that are unsatisfied (or partially unsatisfied) at the end of each period presented are not material to the Company. Contract balances were as follows:
| June 30, 2024 |  | December 31, 2023
| (In thousands)
Contract assets | $ | 50,413 |  |  | $ | 52,648 |
Contract liabilities | (20,369) |  |  | (22,504) |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 691,685 | $ 709,066 | $ 1,341,605 | $ 1,383,931
Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 307,783 | 318,827 | 602,137 | 620,855
Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 184,588 | 191,617 | 363,150 | 376,514
Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 199,314 | 198,622 | 376,318 | 386,562
Life Sciences reagents [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 176,852 | 192,208 | 354,077 | 382,086
Life Sciences instruments [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 86,252 | 100,101 | 167,162 | 196,275
Life Sciences software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 50,743 | 44,044 | 95,645 | 86,433
Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 129,175 | 128,621 | 253,050 | 250,742
Applied genomics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 51,287 | 59,097 | 98,734 | 122,507
Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 197,376 | 184,995 | 372,937 | 345,888
Diagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 377,838 | 372,713 | 724,721 | 719,137
Diagnostics [Member] | Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 139,370 | 134,032 | 277,396 | 272,206
Diagnostics [Member] | Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 117,230 | 116,910 | 226,147 | 221,522
Diagnostics [Member] | Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 121,238 | 121,771 | 221,178 | 225,409
Diagnostics [Member] | Life Sciences reagents [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0
Diagnostics [Member] | Life Sciences instruments [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0
Diagnostics [Member] | Life Sciences software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0
Diagnostics [Member] | Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 129,175 | 128,621 | 253,050 | 250,742
Diagnostics [Member] | Applied genomics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 51,287 | 59,097 | 98,734 | 122,507
Diagnostics [Member] | Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 197,376 | 184,995 | 372,937 | 345,888
Life Sciences [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 313,847 | 336,353 | 616,884 | 664,794
Life Sciences [Member] | Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 168,413 | 184,795 | 324,741 | 348,649
Life Sciences [Member] | Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 67,358 | 74,707 | 137,003 | 154,992
Life Sciences [Member] | Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 78,076 | 76,851 | 155,140 | 161,153
Life Sciences [Member] | Life Sciences reagents [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 176,852 | 192,208 | 354,077 | 382,086
Life Sciences [Member] | Life Sciences instruments [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 86,252 | 100,101 | 167,162 | 196,275
Life Sciences [Member] | Life Sciences software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 50,743 | 44,044 | 95,645 | 86,433
Life Sciences [Member] | Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0
Life Sciences [Member] | Applied genomics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | 0 | 0 | 0 | 0
Life Sciences [Member] | Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesReagentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesInstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_LifeSciencesSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_ReproductiveHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_AppliedGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | pki_MajorGoodsserviceLinesAxis=pki_ImmunodiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pki_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pki_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |